LivaNova (NASDAQ:LIVN) Upgraded by StockNews.com to “Buy”

LivaNova (NASDAQ:LIVN) was upgraded by StockNews.com from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday.

Other equities research analysts have also recently issued research reports about the stock. Barclays raised their price objective on shares of LivaNova from $57.00 to $61.00 and gave the stock an “equal weight” rating in a research note on Monday, February 26th. Needham & Company LLC reaffirmed a “buy” rating and set a $72.00 price objective on shares of LivaNova in a research note on Wednesday, March 20th. Robert W. Baird raised their price objective on shares of LivaNova from $56.00 to $62.00 and gave the stock a “neutral” rating in a research note on Thursday, February 22nd. Finally, Mizuho reaffirmed a “buy” rating and set a $75.00 price objective on shares of LivaNova in a research note on Wednesday, March 27th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $64.40.

LivaNova Stock Performance

LIVN opened at $55.94 on Thursday. LivaNova has a 12-month low of $42.75 and a 12-month high of $59.86. The company has a current ratio of 2.95, a quick ratio of 2.51 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $3.02 billion, a PE ratio of 174.82 and a beta of 0.89. The firm has a 50 day moving average of $53.92 and a two-hundred day moving average of $50.59.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings data on Wednesday, February 21st. The company reported $0.87 EPS for the quarter, topping analysts’ consensus estimates of $0.77 by $0.10. The business had revenue of $310.10 million for the quarter, compared to analysts’ expectations of $287.65 million. LivaNova had a net margin of 1.53% and a return on equity of 12.23%. The business’s revenue was up 12.8% on a year-over-year basis. During the same quarter last year, the company earned $0.81 EPS. On average, analysts anticipate that LivaNova will post 3.01 EPS for the current year.

Institutional Investors Weigh In On LivaNova

Institutional investors have recently added to or reduced their stakes in the stock. Adage Capital Partners GP L.L.C. acquired a new stake in LivaNova in the 3rd quarter valued at $7,932,000. Kingdon Capital Management L.L.C. acquired a new stake in LivaNova during the 3rd quarter worth $7,123,000. Vanguard Group Inc. boosted its stake in LivaNova by 6.0% during the 3rd quarter. Vanguard Group Inc. now owns 1,770,277 shares of the company’s stock worth $93,612,000 after purchasing an additional 100,133 shares during the last quarter. Barclays PLC boosted its stake in LivaNova by 15.9% during the 3rd quarter. Barclays PLC now owns 851,870 shares of the company’s stock worth $45,047,000 after purchasing an additional 116,842 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new stake in LivaNova during the 3rd quarter worth $1,672,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.